Prevent Issues With Xeljanz and Other "JAK Inhibitors"

Labeling changes will bring attention to safe use of "Janus kinase (JAK) inhibitors"...Xeljanz, Olumiant, and recently approved Rinvoq.

There's an uptick in use of these specialty meds for rheumatoid arthritis and other autoimmune diseases...since they're taken orally.

Now there's a boxed warning about an increased risk of blood clots with Xeljanz (tofacitinib). Olumiant (baricitinib) and Rinvoq (upadacitinib) also carry this warning.

Get unlimited access through an Enterprise license

Hospital Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals